Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
BACKGROUND
Readmission within 30days is a measure of care quality. Ovarian cancer patients are at high risk for readmission, but specific risk factors are not defined. This study was designed to determine risk factors in patients with ovarian cancer receiving upfront surgery and chemotherapy.


METHODS
The study population was enrolled to GOG 0218. Factors predictive of admission within 30days of a previous admission or 40days of cytoreductive surgery were investigated. Categorical variables were compared by Pearson chi-square test, continuous variables by Wilcoxon-Mann-Whitney test. A logistic regression model was used to evaluate independent prognostic factors and to estimate covariate-adjusted odds. All tests were two-tailed, α=0.05.


RESULTS
Of 1873 patients, 197 (10.5%) were readmitted, with 59 experiencing >1 readmission. One-hundred-forty-four (73%) readmissions were post-operative (readmission rate 7.7%). Significant risk factors include: disease stage (stage 3 vs 4, p=0.008), suboptimal cytoreduction (36% vs 64%, p=0.001), ascites, (p=0.018), BMI (25.4 vs 27.6, p<0.001), poor PS (p<0.001), and higher baseline CA 125 (p=0.017). Patients readmitted within 40days of surgery had a significantly shorter interval from surgery to chemotherapy initiation (22 versus 32days, p<0.0001). Patients treated with bevacizumab had higher readmission rates in the case of patients with >1 readmission. On multivariate analysis, the odds of re-hospitalization increased with doubling of BMI (OR=1.81, 95% CI: 1.07-3.07) and PS of 2 (OR=2.05, 95% CI 1.21-3.48).


CONCLUSIONS
Significant risk factors for readmission in ovarian cancer patients undergoing primary surgery and chemotherapy include stage, residual disease, ascites, high BMI and poor PS. Readmissions are most likely after the initial surgical procedure, a discrete period to target with a prospective intervention.
University of Virginia Health Systems, Division of Gynecology Oncology, P.O. Box 800712, Charlottesville, VA 22908, United States. Electronic address: lduska@virginia.edu.
Linda R
LR
Duska
NRG Oncology/Gynecologic Oncology Group, Statistics & Data Center, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, United States. Electronic address: james.j.java@gmail.com.
James J
JJ
Java
Division of Gynecologic Oncology, The Ohio State University College of Medicine, 320 West 10th Avenue, M210 Starling Loving Hall, Columbus OH 43210, United States. Electronic address: david.cohn@osumc.edu.
David E
DE
Cohn
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Pennsylvania, 3400 Civic Center Boulevard, SCTR 8-104 Philadelphia PA, United States. Electronic address: robert.burger@uphs.upenn.edu.
Robert A
RA
Burger
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001201:Ascites / Q000209:etiology; D000068258:Bevacizumab / Q000008:administration & dosage; D015992:Body Mass Index; D018394:CA-125 Antigen / Q000097:blood; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D065426:Cytoreduction Surgical Procedures; D004311:Double-Blind Method; D005185:Fallopian Tube Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D009765:Obesity / Q000150:complications; D010051:Ovarian Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D010359:Patient Readmission / Q000706:statistics & numerical data*; D010534:Peritoneal Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D012307:Risk Factors; D013997:Time Factors
D018394:CA-125 Antigen; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel
Chemotherapy; Ovarian cancer; Readmissions